Delcath Systems Schedules Conference Call to Report 2021 First Quarter Financial Results

Rhea-AI Summary

Delcath Systems, Inc. (DCTH) announced a conference call scheduled for May 11, 2021, to discuss its first-quarter results ending March 31, 2021. The call is set for 8:30 AM ET, and participants can join via phone or online. Delcath specializes in interventional oncology, focusing on rare liver cancers with its investigational product, HEPZATO KIT, designed for targeted chemotherapy delivery. While HEPZATO KIT is not FDA-approved in the U.S., it is CE-marked in Europe. The company has paused its ALIGN Trial for intrahepatic cholangiocarcinoma to reevaluate the trial's design.

Positive

• None.

Negative

• HEPZATO KIT is not approved by the FDA for sale in the U.S.
• ALIGN Trial for intrahepatic cholangiocarcinoma has been paused for reevaluation.

NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on May 11, 2021 at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2021. 

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

Date: May 11, 2021 
Time: 8:30 AM Eastern Time 
Toll Free: 888-506-0062; Entry Code: 626332
International: 973-528-0011; Entry Code: 626332

The call will also be available over the Internet and accessible at: https://www.webcaster4.com/Webcast/Page/2475/41204  

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product – HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) – is designed to administer high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects. In addition to the FOCUS Trial, which is investigating the treatment of mOM, we have initiated a global Phase 3 clinical trial for intrahepatic cholangiocarcinoma (ICC) called the ALIGN Trial. We have paused our work on the ALIGN Trial while we reevaluate the trial design. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara
(646)-755-7412
james@haydenir.com

FAQ

When is Delcath Systems' conference call for Q1 2021 earnings?

Delcath Systems will host its Q1 2021 earnings conference call on May 11, 2021, at 8:30 AM Eastern Time.

What is the focus of Delcath Systems' investigational product, HEPZATO KIT?

HEPZATO KIT is designed for high-dose chemotherapy administration to the liver while minimizing systemic exposure.

Is HEPZATO KIT approved for use in the U.S.?

No, HEPZATO KIT has not yet been approved by the FDA for sale in the U.S.

What is the status of the ALIGN Trial by Delcath Systems?

The ALIGN Trial has been paused as Delcath Systems reevaluates the trial design.